CRISPR Therapeutics Ownership | Who Owns CRISPR Therapeutics?

Overview Forecast RevenueFinancials Chart

CRISPR Therapeutics Ownership Summary

CRISPR Therapeutics is owned by 73.72% institutional investors, 1.57% insiders, and 24.70% retail investors. Ark investment management is the largest institutional shareholder, holding 11.52% of CRSP shares. ARK Innovation ETF is the top mutual fund, with 7.78% of its assets in CRISPR Therapeutics shares.

CRSP Ownership Benchmark

Type	Name	% Inst	% Insiders	% Retail
Stock	CRISPR Therapeutics	73.72%	1.57%	24.70%
Sector	Healthcare Stocks	231.98%	10.74%	-142.72%
Industry	Biotech Stocks	381.47%	10.55%	-292.02%

Institutional Shareholders

Top Institutional Shareholders by Total Shares

Holder	Shares	% Holding	Value
Ark investment management	10.52M	11.52%	$551.78M
Blackrock funding, inc. /de	7.51M	8.22%	$393.73M
Capital investors	5.89M	6.45%	$309.02M
Orbis allan gray	4.98M	5.72%	$322.89M
State street	4.01M	4.60%	$259.71M
T. rowe price investment management	3.28M	3.77%	$212.75M
Gsk	3.22M	3.53%	$168.89M
Blackrock	2.78M	3.40%	$150.03M
Ubs group	2.52M	2.76%	$132.37M
Vanguard group	2.27M	2.48%	$118.95M

Top Institutional Shareholders by % of Total Assets

Holder	Shares	% Assets	Value
Gsk	3.22M	21.14%	$168.89M
Sr one capital management, lp	2.04M	15.14%	$106.91M
Spear rsc	165.00K	6.29%	$8.91M
Versant venture management	148.83K	5.17%	$7.80M
Ecor1 capital	1.39M	4.32%	$90.04M
Nea management company	1.06M	3.76%	$68.61M
Ark investment management	10.52M	3.66%	$551.78M
Green alpha advisors	55.74K	2.68%	$2.92M
Contrarius investment management	685.72K	2.32%	$37.04M
Eagle health investments lp	197.00K	1.87%	$10.64M

Top Buyers

Holder	Shares	% Assets	Change
Gsk	3.22M	21.14%	3.22M
Orbis allan gray	4.98M	1.39%	2.22M
State street	4.01M	0.01%	736.64K
Ark investment management	10.52M	3.66%	735.08K
Millennium management	583.73K	0.01%	575.24K

Top Sellers

Holder	Shares	% Assets	Change
Two sigma advisers, lp	572.97K	0.07%	-771.73K
Morgan stanley	667.06K	0.00%	-730.80K
National bank of canada /fi/	9.82K	0.00%	-725.78K
Baker bros. advisors lp	-	-	-654.10K
Bellevue group	-	-	-610.00K

New Positions

Holder	Shares	% Assets	Change	Value
Gsk	3.22M	21.14%	3.22M	$168.89M
Norges bank	490.21K	0.00%	490.21K	$25.71M
Beck bode	98.80K	0.86%	98.80K	$5.18M
Wellington management group llp	36.49K	0.00%	36.49K	$2.36M
Voloridge investment management	32.39K	0.01%	32.39K	$2.10M

Sold Out

Holder	Change
Tortoise investment management	-1.00
Activest wealth management	-1.00
Carolina wealth advisors	-1.00
Impact partnership wealth	-1.00
Frazier financial advisors	-2.00

Institutional Ownership Trends

Date	Holdings	Change %	Shares	Change %	Ownership	Change %	Increased Position	Change %	Decreased Position	Change %
Dec 31, 2025	430	-10.60%	67,314,484	-6.81%	73	1.07%	208	-7.96%	108	-11.48%
Sep 30, 2025	461	-2.12%	71,905,056	-0.80%	82	1.19%	220	-6.78%	117	15.84%
Jun 30, 2025	457	9.33%	72,312,350	12.69%	83	1.49%	228	31.03%	101	-2.88%
Mar 31, 2025	16	-96.30%	3,317,986	-94.86%	3	0.07%	8	-95.58%	3	-97.52%
Dec 31, 2024	420	-5.83%	64,513,268	8.48%	76	1.57%	174	-	118	-10.61%

Top Mutual Funds Shareholders

Holder	Shares	% Holding	Change
ARK Innovation ETF	7.47M	7.78%	113.45K
ARK Disruptive Innovation Full Composite	7.23M	7.53%	355.23K
iShares Russell 2000 ETF	2.10M	2.19%	2.10M
ARK Genomic Revolution ETF	2.05M	2.13%	-
Capital Group New Perspective Comp	1.94M	2.03%	-202.29K
American Funds New Perspective A	1.94M	2.03%	-202.29K
ARK Genomic Revolution	1.92M	2.00%	212.13K
State Street® SPDR® S&P® Biotech ETF	1.74M	1.81%	-9.32K
American Funds SMALLCAP World A	1.65M	1.72%	-
SPDR® S&P Biotech ETF	1.40M	1.53%	3.11K

Recent Insider Transactions

Date	Name	Role	Activity	Value
Feb 19, 2026	Kulkarni Samarth	Chief Executive Officer	Sell	$366.32K
Feb 19, 2026	KASINGER JAMES R.	General Counsel and Secretary	Sell	$111.05K
Apr 03, 2025	Patel Naimish	Chief Medical Officer	Buy	$49.70K
Jan 22, 2026	Prasad Raju	Chief Financial Officer	Sell	$2.10M
Jan 20, 2026	Kulkarni Samarth	Chief Executive Officer	Sell	$446.34K

Insider Transactions Trends

Date	Buy	Sell
2026 Q1	-	9
2025 Q4	-	6
2025 Q3	4	1
2025 Q2	-	1
2025 Q1	1	17

CRSP Ownership FAQ

Who Owns CRISPR Therapeutics?

CRISPR Therapeutics shareholders are primarily institutional investors at 73.72%, followed by 1.57% insiders and 24.71% retail investors. The average institutional ownership in CRISPR Therapeutics's industry, Biotech Stocks , is 381.47%, which CRISPR Therapeutics falls below.

Who owns the most shares of CRISPR Therapeutics?

CRISPR Therapeutics’s largest shareholders are Ark investment management (10.52M shares, 11.52%), Blackrock funding, inc. /de (7.51M shares, 8.22%), and Capital investors (5.89M shares, 6.45%). Together, they hold 26.20% of CRISPR Therapeutics’s total shares outstanding.

Does Blackrock own CRISPR Therapeutics?

Yes, BlackRock owns 3.40% of CRISPR Therapeutics, totaling 2.78M shares as of Jun 2024. This represents 0.00% of BlackRock's total assets, with a market value of 150.03M$. In the last quarter, BlackRock increased its holdings by 231.42K shares, a 9.09% change.

Who is CRISPR Therapeutics’s biggest shareholder by percentage of total assets invested?

Gsk is CRISPR Therapeutics’s biggest shareholder by percentage of total assets invested, with 21.14% of its assets in 3.22M CRISPR Therapeutics shares, valued at 168.89M$.

Who is the top mutual fund holder of CRISPR Therapeutics shares?

ARK Innovation ETF is the top mutual fund holder of CRISPR Therapeutics shares, with 7.78% of its total shares outstanding invested in 7.47M CRISPR Therapeutics shares.

Try Tickergate Pro Free

Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)

Customize your own personal stocks lists, views and charts
Choose from hundreds of fields, up to 15 years of history
Conduct deep comparison analysis

Discover trending investment themes
Find your next best investment
Research stocks using tools